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Abstract 
Type 2 Diabetes Mellitus (T2DM) leads to bone fragility and predisposes to increased risk of 
fracture, poor bone healing and other skeletal complications. In addition, some anti-diabetic 
therapies for T2DM can have notable detrimental skeletal effects. Thus an appropriate 
therapeutic strategy for T2DM should not only be effective in re-establishing good glycaemic 
control but also in minimising skeletal complications. There is increasing evidence that 
Glucagon-like peptide-1 receptor (GLP-1r) agonists, now greatly prescribed for the treatment 
of T2DM, have beneficial skeletal effects although the underlying mechanisms are not 
completely understood. This review provides an overview of the direct and indirect effects of 
GLP-1RAs on bone physiology, focusing on bone quality and novel mechanisms of action on 
the vasculature and hormonal regulation. The overall experimental studies indicate 
significant positive skeletal effects of GLP-1RAs on bone quality and strength although their 
mechanisms of actions may differ according to various GLP-1RAs and clinical studies 
supporting their bone protective effects are still lacking. The possibility that GLP-1RAs could 
improve blood supply to bone, which is essential for skeletal health, is of major interest and 
suggests that GLP-1 anti-diabetic therapy could benefit the rising number of elderly T2DM 
patients with osteoporosis and high fracture risk.  
 
Lay Abstract 
Bone weakening is an important complication in individuals with type 2 diabetes (T2DM). 
This review summarises the effects on skeletal health of drugs that are similar to the 
hormone Glucagon-like peptide-1 (GLP-1), which are now used increasingly for the 
treatment of T2DM and could lead to a stronger skeleton.  
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1 Introduction 
Diabetes mellitus (DM) is a chronic disease that progresses worldwide at alarming rates. For 
instance, in 2013, it has been estimated that DM affected 382 million individuals [1]. 
Projections for 2035 indicate a global burden of 55% to reach up to 592 million individuals 
[1]. Associated complications are commonly cardio-vascular events, nephropathy, 
retinopathy, neuropathy and bone fragility that dampen the quality of life of affected 
individuals.  
Type 2 diabetes mellitus (T2DM) is by far the most common form of DM and is characterised 
by chronic hyperglycaemia and hyperinsulinemia mostly caused by insulin resistance (IR) in 
peripheral tissues such as the liver and muscle. The aetiology of bone fragility in T2DM is 
unclear. Indeed, bone mineral density is normal or slightly elevated in T2DM despite an 
increase risk of femoral neck fracture, suggesting alterations of bone "quality" rather than 
bone mass [2-4]. Bone quality is an umbrella term that regroups factors such as bone 
microarchitectures, tissue material properties and bone toughness [5]. Another important 
contributor for bone fracture is represented by an increased risk in falls in this population [6, 
7]. At the cellular and molecular levels, T2DM is characterised by a reduction in bone 
turnover suggesting modifications of bone cell behaviours [8]. Furthermore, low testosterone 
and vitamin D levels, and high plasma sclerostin, are common features observed in T2DM 
patients [9].  
Current treatment options of T2DM rely on lifestyle intervention and oral or injectable drugs, 
when needed, to reach an HbA1C level of 7% or less. Among the most prescribed drugs, the 
glucagon-like peptide-1 receptor agonists (GLP-1RAs) have recently attracted attention as 
Glp-1r knockout animals and GLP-1 supplemented animals exhibited modifications of bone 
strength and quality as described below.  
Endogenously, GLP-1 is produced by post-translational processing of the glucagon gene in 
enteroendocrine cells, mainly L-cells [10]. Two forms of GLP-1 are produced in the intestine, 
GLP-17-36NH2 and GLP-17-37 although the major circulating form is GLP-17-36NH2 [11]. L-cells 
are an open type endocrine cells highly polarised with secretory granules at their basolateral 
pole ready to be released in the capillary network running through the lamina propria. This 
secretion is regulated by intraluminal contents, neural stimuli and hormones [12]. Beyond its 
endocrine mode of action, GLP-1 has also been suspected to act via the autonomous 
nervous system and hypothalamic and brainstem nuclei [13].  
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To act, GLP-1 engages its receptor; the GLP-1r that is coded by the human GLP1R gene 
comprising 13 exons that span approximately 13.8kb [14] and localised on chromosome 
6p21 [15]. The GLP-1r is expressed in the endocrine pancreas, gastro-intestinal tract, lung, 
heart, kidney and several regions of the brain [12]. Recent evidences also suggest that GLP-
1 can bind in specific circumstances to the glucagon receptor [16]. The principal 
physiological role of GLP-1 is to potentiate glucose-dependent insulin secretion [17]. 
Extrapancreatic actions of GLP-1 results in reduction of food intake through the CNS, 
inhibition of gastric emptying, positive actions on the cardiovascular system and a role in 
energy expenditure [17].  
GLP-1RAs are GLP-1 with extended half-life to be more resistant to degradation by the 
dipeptidyl peptidase-4 (DPP-4) enzyme. Several molecules listed in Table 1 have been 
developed by the pharmaceutical industry and now been approved for the treatment of 
T2DM. The aim of the present review is to provide the reader with a comprehensive analysis 
of the effects of GLP-1RAs on bone physiology with special focuses on the mode of action 
including effects on bone quality, blood flow to bone, and on the hormonal regulation of bone 
metabolism.   
 
2 Skeletal effects of GLP-1 agonists: direct and/or indirect mechanisms of 
action 
 
2.1 Clinical studies 
Clinical data on the skeletal effects of GLP-1RAs are scarce. Bone turnover markers and 
bone mineral density have been assessed in T2DM patients treated with exenatide and 
liraglutide. However, all these studies reported no effects of GLP-1RA treatment on 
circulating bone markers or bone mineral density [18-20]. Interestingly, the effects of 
liraglutide administration on bone turnover markers have been reported not in diabetic but in 
the obese population for the weight-loss action of liraglutide. In that study, bone formation 
was improved as indicated by higher values for N-terminal propeptide of type 1 procollagen 
reported in the liraglutide arm, but no effects on bone resorption were observed [21]. 
Two meta-analyses have also been performed on the use of GLP-1RA and the possible 
effects of these medications on fracture risk. One meta-analysis found beneficial effects of 
liraglutide in reducing the occurrence of bone fractures [22]. The other meta-analysis found 
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neutral effect of GLP-1RA as compared with other anti-diabetic medications [23]. 
Interestingly, Driessen and colleagues [24, 25] investigated in the British and Danish 
populations the incidence of bone fracture in GLP-1RA takers as compared with non-takers. 
No significant difference was observed and they suggested that the effect of GLP-1RAs was 
neutral in the human diabetic population.  
 
2.2 In vivo studies 
The first understanding of GLP-1 actions in skeletal physiology arises from Glp1-r KO 
mouse. At 10 weeks of age, these mice exhibited a small reduction in bone mass associated 
with an increased number of osteoclasts and eroded surfaces [26]. On the other hand, the 
mineral apposition and bone formation rates appeared unaffected by GLP-1r inactivation 
[26]. Similarly, observations in the same KO model at 16 weeks of age and in the double 
incretin receptor knockout model at 26 weeks of age corroborated these findings [27, 28]. 
Taken together these results suggested a control of bone resorption (osteoclast 
differentiation and/or action) by the GLP-1r. According to the literature, this effect on 
resorption seems to be indirect through a reduction in calcitonin gene expression in GLP-1r-
deficient animals [26] but further evidences are warranted.  
While it is well established that GLP-1RAs increase bone mass (see paragraph 3), previous 
investigations of their effects on bone turnover in rodents are conflicting. It has been 
reported that 3 μg/kg/day and 4.2 μg/kg/day exenatide induced bone formation by osteoblast 
activation in old ovariectomised (OVX) rats [29] and in hindlimb-unloading rats [30] by 
promoting the osteogenic differentiation and inhibiting BMSC adipogenic differentiation. A 
decrease of osteoclastic surfaces was also observed [29]. In contrast, we found no effect of 
both 10 μg/kg/day exenatide and 0.3 mg/kg/day liraglutide on bone formation in OVX mice 
and a slight increase of osteoclastic surfaces with the drug [31]. Moreover, our recent results 
suggest that exenatide increases bone formation in a T2DM mouse model but not in control 
mice while there was no effect of the drug on bone resorption (Pereira M, Gohin S, Roux JP, 
Cleasby ME, Mabilleau G, Chenu C, manuscript in revision). Thus, it is still unclear whether 
the mechanism of action of GLP-1RAs in bone is direct or indirect and targeting bone 
formation or resorption.  
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2.3 In vitro studies 
While several studies have reported that GLP-1RAs could have beneficial effects on the 
skeleton, the downstream molecular mechanisms underlying the osteogenic effect have not 
been identified [32, 33]. It is indeed unclear whether the mechanism of action of GLP-1RAs 
in bone is direct, through a functional GLP-1r expressed by bone cells, or indirect, via an 
increase in calcitonin production by the thyroid C-cell which inhibits bone resorption [26]. 
Furthermore, the presence and the identity of the GLP-1r in bone were controversial until 
recently and thus the basis for direct skeletal effects of GLP-1 has not been established. 
We recently demonstrated that GLP-1 might directly affect bone cells via a GLP-1r identified 
in primary mouse osteoblasts isolated from calvaria and bone marrow-derived osteoclasts 
[31] and this was confirmed in situ using a GLP-1r antibody (abcam). Similarly, other studies 
showed that mouse osteoblast-like MC3T3-E1 cells express a functional receptor for GLP-1 
[34]. However this receptor could be different from the cAMP-linked GLP-1r expressed in the 
pancreas, but its existence implies that a direct skeletal action of GLP-1 may be possible 
[34, 35]. In contrast, expression of the pancreatic-type GLP-1r mRNA was identified in 
human osteoblastic cell lines deriving from osteosarcomas, but its expression was 
dependent on the stage of osteoblastic development [36]. However, other study failed to 
demonstrate the presence of GLP-1r at the mRNA level in primary murine osteoblasts or 
osteoclasts [37]. Similarly, the presence of the pancreatic GLP-1r in osteocytic cells was 
controversial as it has been reported in some cell lines, but not all [31, 38], as well as in 
osteocytes in rat femurs [38]. 
The presence of GLP-1r in bone cells in vitro and in situ implies that GLP-1RAs could have 
direct effects on bone cells. A study has indeed identified potential skeletal beneficial effects 
of 10 nM of exenatide by promoting osteoblastogenesis and restraining adipogenesis 
through a β-catenin pathway, during BMMSC differentiation [30]. Despite increased 
osteoblastogenesis, no direct effect of GLP-1RAs on bone nodule mineralisation in vitro was 
shown with up to 100uM of exenatide and 1000nM of liraglutide [29, 31]. It is well 
established that exposure of primary osteoblast cells to high glucose levels inhibits in vitro 
bone nodule formation [39, 40]. Interestingly, despite no effect of exenatide on bone 
formation in normal glucose conditions, our results demonstrate that it can reduce the 
deleterious effect of glucose on bone formation in vitro, in a dose-dependent manner 
(Pereira M, Gohin S, Roux JP, Cleasby ME, Mabilleau G, Chenu C, manuscript in revision). 
This could be due to upregulated GLP-1r expression in high glucose conditions, which could 
in turn magnify the effect of GLP-1RAs [34]. Regarding the effects of GLP-1RAs on 
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osteoclastogenesis in vitro, we showed that both liraglutide and exenatide increased 
osteoclastogenesis, while decreasing the area resorbed per osteoclast, suggesting that 
GLP-1RAs stimulate osteoclastic differentiation but impair their resorptive activity [31].  
 
3 GLP-1RAs and bone quality 
Unfortunately, as neither peripheral quantitative computed tomography (pQCT) nor iliac crest 
bone biopsy are part of the usual care in diabetic clinical trials, human data on the effects of 
GLP-1RAs on all aspects of bone quality are presently missing. As such, the following 
summary of action of GLP-1RA is based on pre-clinical data obtained in animal models. 
Several animal models of either osteoporosis or T2DM have been used to assess the effects 
of two GLP-1RAs, exenatide and liraglutide, on bone quality and strength. However, data 
concerning potential bone effects of other GLP-1RAs, and especially those administered 
once weekly, are currently missing. Mice presenting a deletion of GLP-1r have also been 
generated and represented a suitable model to investigate the role of the GLP-1/GLP-r 
pathway in bone.  
 
3.1 Effects of GLP-1RAs on bone strength  
Our knowledge of the effects of the GLP-1/GLP-1r pathway on bone strength has been 
markedly improved by the use of Glp-1r KO mice. Indeed, although these animals are not 
diabetic, they exhibited a significant reduction in bone strength represented by lower ultimate 
load and stiffness [37].  Bone strength in response to GLP-1RA has also been investigated 
in osteoporotic animal models generated either by ovariectomy or disuse. In ovariectomy-
induced osteoporosis, the use of exenatide at a concentration as low as 1 µg/kg/day for 16 
weeks, led to improvement in maximum load and stiffness as well as Young’s modulus and 
ultimate stress, suggesting amelioration in bone microarchitecture and/or tissue material 
properties [29]. In the rat tail suspension model, the administration of exenatide (4.2 
µg/kg/day) for 4 weeks resulted in higher value for maximum loading, stiffness, stress and 
Young’s modulus, suggesting here again ameliorations in bone microarchitecture and/or 
tissue material properties [30]. Our very recent data (Pereira M, Gohin S, Roux JP, Cleasby 
ME, Mabilleau G, Chenu C, manuscript in revision) showed a reduction in bone strength of 
diabetic db/db mice with significantly lower values for ultimate load, stiffness and work-to-
failure, but four weeks administration of exenatide in these diabetic animals did not have any 
significant effect on bone strength parameters.  
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3.2 Effects of GLP-1RAs on bone microarchitecture 
In Glp-1r KO animals, unpublished observations from our group, revealed that these animals 
presented with a reduction in cancellous bone volume associated with a lower trabeculae 
numbers and higher trabecular spacing. These data have been confirmed by the elegant 
study of Yamada et al. [26] who reported a significant reduction in cancellous bone mineral 
density in the same transgenic animal model. Alterations of cortical bone in this mouse 
model were also evidenced with lower outer bone diameter and cortical thickness [37]. 
Exenatide and liraglutide have been used as a treatment option in pre-clinical animal models 
of osteoporosis. Exenatide demonstrated positive effects on trabecular bone 
microarchitecture in the axial and appendicular skeleton evidenced by amelioration of 
structural parameters in lumbar vertebra and long bones as early as 4 weeks treatment. 
Indeed, exenatide resulted in higher bone volume/total volume (BV/TV) values (24% to 
148%, depending on dose and treatment duration) and higher values for trabecular number 
(Tb.N), thickness (Tb.Th) and reduction in separation (Tb.Sp) [29-31, 41].  Liraglutide also 
showed improvement in trabecular bone microarchitecture but these effects seemed 
restricted to long bones with very poor action on the axial skeleton [31, 42]. The effects of 
GLP-1RA on cortical microarchitecture were only observed after a minimum of 8 weeks 
treatment with exenatide or liraglutide, but highlighted significant increases in cortical 
thickness with 20µg/kg/day of exenatide or 0.6mg/kg/day of liraglutide [41, 42].  
In opposition to what is commonly observed in humans, animal models of T2DM exhibit 
significant alteration of trabecular and cortical microarchitectures. The effects of GLP-1RA 
use in diabetic animal models have also been reported. The use of exenatide at a regimen of 
10 µg/kg/day for 3 days in T2DM animals resulted in improvement in trabecular 
microarchitecture at the femur and in the lumbar spine [43, 44]. Four weeks treatment with 
10 µg/kg/day of exenatide also improved trabecular bone mass and architecture in the tibiae 
of db/db mice (Pereira M, Gohin S, Roux JP, Cleasby ME, Mabilleau G, Chenu C, 
manuscript in revision). The use of liraglutide was also investigated in the Goto-Kakizaki 
T2DM rat model at a dose of 0.4 mg/kg/day for 4 weeks. This regimen led to significant 
improvement in trabecular and cortical bone microarchitectures in the femur and lumbar 
vertebra [45].    
The effects of liraglutide on bone microarchitecture have also been investigated in a T1DM 
mouse model. In this study, the administration of 0.093 mg/kg/day liraglutide for 3 weeks did 
not demonstrate ameliorations of neither trabecular nor cortical microarchitectures [46].  
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3.3 Effects of GLP-1RAs on tissue material properties 
With respect to the improvement in bone strength and intrinsic properties (Young’s modulus, 
stress), that are independent of the bone architecture, one could suspect action of GLP-1RA 
on tissue material properties. However, very little information has been reported. Tissue 
material properties represent a set of parameters that describe the modification of 
biochemical composition or organisation of the bone matrix at the molecular and nanoscale 
levels [5]. This encompasses for a thorough assessment of the mineral and collagen 
compartment. Most of our knowledge on the action of GLP-1 on tissue material properties is 
based on Glp1r KO mice. Indeed, in these animals, a significant reduction in enzymatic 
collagen cross-linking has been evidenced and associated with alteration of bone strength at 
the tissue level [37]. However, in opposition to what has been seen with the sister incretin 
hormone GIP, Glp-1r deletion did not alter the mineral compartment [47].  Data regarding the 
potential effects of GLP-1RAs on tissue material properties in osteoporotic animals are 
lacking. However, an elegant study conducted by Mansur et al. investigated the effects of 
0.093 mg/kg/day liraglutide over a period of 3 weeks in a T1DM mouse model [46]. These 
authors reported no amelioration of enzymatic collagen cross-linking or collagen glycation 
but an unexpected reduction in collagen destruction [46].  Interestingly, we recently showed 
that collagen maturity was altered in db/db mice and that exenatide treatment at a dose 
regimen of 10µg/kg/day reversed the impairment in collagen maturity induced by diabetes 
(Pereira M, Gohin S, Roux JP, Cleasby ME, Mabilleau G, Chenu C, manuscript in revision). 
 
4 GLP-1RAs and blood flow to bone 
Diabetes leads to poor circulation and vascular diseases are the principal causes of death 
and disability in people with diabetes. Consequently, wound and fracture healing are 
delayed in diabetic patients, one of the main reasons being the impairment in vascularisation 
[48, 49]. Particularly, diabetes was shown to induce a decrease in endothelial progenitor 
cells (EPC) that are important for angiogenesis and vascular repair [50]. It is now well 
established that blood flow is crucial to bone vascular function and osteogenesis [51] and 
that disrupted blood supply to bone is associated with reduced bone mass, osteonecrosis 
and impaired bone regeneration [49, 52, 53]. Very little work has however examined whether 
the bone vasculature and bone blood flow are reduced in diabetic bone and if it is possible to 
restore them with the use of anti-diabetic drugs. Fajardo [54] recently reviewed the literature 
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regarding the microvascular complications in diabetic bone but evidences are still lacking to 
support the link between skeletal fragility in diabetes and those vascular complications.  
The potential for GLP-1RAs to enhance vascular function has been demonstrated in a few 
studies [55-58]. The improvement of vascular endothelial function restores impaired glucose 
tolerance by ameliorating insulin resistance in skeletal muscle [59]. Interestingly, two weeks 
administration of 0.5μg/kg/d exenatide was shown to accelerate diabetic wound healing by 
increasing angiogenesis in the wound and the number of circulating EPCs [60]. Our recent 
work also demonstrates that 10µg/kg exenatide can have beneficial effects on bone 
vascularisation in diabetic bone by acutely increasing blood flow to bone in db/db mice 
(Pereira M, Gohin S, Roux JP, Cleasby ME, Mabilleau G, Chenu C, manuscript in revision). 
This suggests that the increased bone formation induced by exenatide treatment in diabetic 
mice could be attributed in part to this increased skeletal perfusion. More work is therefore 
needed to examine whether skeletal perfusion is linked to bone formation in diabetic bone 
and if GLP-1RAs could be used as treatment to increase vascularisation in diabetic patients 
with poor fracture healing.  
 
5 GLP-1 RA and hormones that regulate bone metabolism 
A major breakthrough in the bone research field has been the finding that bone is an 
endocrine organ that can affect other organs via the release of hormones such as 
osteocalcin and sclerostin. There are increasing reports showing that GLP-1RAs can affect 
the release of these hormones by bone cells in vitro and in animal models but the clinical 
evidence is however still very scarce.  
 
5.1 Sclerostin 
The discovery of the importance of the Wnt/ catenin pathway for bone formation has led to 
extensive work examining the function of sclerostin in bone. Sclerostin is a product of the 
SOST gene expressed mainly by osteocytes which is secreted and acts as a potent 
antagonist of Wnt signalling [61]. Its deficiency or its pharmacological neutralisation 
increases bone formation, making it a potential target for treatment of bone diseases 
associated with bone loss, such as osteoporosis [62, 63]. Several studies have shown that 
serum sclerostin levels are elevated in diabetic patients, suggesting that sclerostin could 
contribute to the decreased bone formation observed in diabetic patients [64-66]. There are 
however conflicting results regarding the changes in serum sclerostin levels observed 
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among studies, partly due to the fact that sclerostin could be derived from other non-skeletal 
sources so that serum levels may not reflect the production in bone [67] and partly because 
the ELISA kits for sclerostin measurements were found to lack accuracy [68, 69].  
To address this issue, a few studies were conducted examining if sclerostin production by 
osteocytes is modified in bone of diabetic rodents or in vitro when osteocytes are cultured in 
high glucose levels. Inconsistencies were observed [39, 70] and in vitro studies are however 
constrained by the fact that only osteocyte cell lines can be used and they are discrepancies 
regarding their production of sclerostin [39, 70]. Our recent study shows that the impaired 
bone microarchitecture and cellular turnover associated with T2DM-like conditions in diabetic 
ZDF rats are not correlated with changes in serum sclerostin levels, bone sclerostin 
expression or osteocyte viability [39]. On the other hand, high fat diet in mice resulted in 
increased serum sclerostin and dramatic alterations of osteocyte network organisation [71]. 
Few studies have investigated if GLP-1RAs could affect sclerostin production. Although most 
data agrees that GLP-1r is mainly expressed in immature osteoblasts, GLP-1r can be 
present in osteocytes where it co-localise with sclerostin [38], suggesting that GLP-1RAs 
may affect sclerostin production by osteocytes. Kim et al have indeed shown that sclerostin 
levels are increased in diabetes and can be down-regulated by exenatide treatment [38]. 
More recently, they demonstrate that the DPP-4 inhibitor vildagliptin lowers the increases 
levels of sclerostin induced by thiazolidinedione [72]. Our own results are more conflicting as 
we showed that exenatide but not liraglutide decreased sclerostin levels in OVX mice [31], 
but  in contrast, sclerostin levels were increased with exenatide in diabetic mice while 
unchanged in IR rats (Pereira M, Gohin S, Roux JP, Cleasby ME, Mabilleau G, Chenu C, 
manuscript in revision). This may reflect differences in the currently available commercial 
assays for the measurement of sclerostin or the animal model making presently the 
measurement of serum sclerostin not very useful as a predictive biomarker for impaired 
bone formation in T2DM.  
 
5.2 Osteocalcin 
Osteocalcin (OC) is a small protein produced in bone by osteoblasts during bone formation 
which has traditionally been used as a serum marker for bone formation [73]. This protein 
has however regained a different interest in recent years due to the demonstration that when 
it is in its uncarboxylated form (GluOC) which does not bind to bone, it can circulate, act as a 
hormone and regulate glucose metabolism [74]. GluOC can stimulate the release of GLP-1 
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from the small intestine and therefore indirectly promote insulin secretion by the pancreatic 
cell [75].  
It was suggested that incretins could contribute to whole body energy metabolism by 
modulating osteocalcin synthesis in osteoblasts. The effects of GLP-1RAs on osteocalcin 
production by osteoblasts were examined and once again the results are inconsistent. While 
Kim et al [38], Nuche-Berenguer et al [44] demonstrate an increase in serum osteocalcin 
levels with exendin-4 in T2DM and IR rats, this was not the case with liraglutide treatment 
[21, 76]. A recent study demonstrates that incretins inhibit thyroid hormone-stimulated 
osteocalcin synthesis in osteoblasts in vitro, suggesting that incretins could stimulate bone 
formation by reducing the osteocalcin levels [77], although this is not confirmed in vivo. 
Osteocalcin concentration significantly increases during calcification and arterial calcification 
is an important complication of diabetes due to the differentiation of vascular smooth muscle 
cells into osteoblast-like cells. Although some work demonstrates an inhibitory effect of GLP-
1RAs on vascular calcifications, this is not always the case [78, 79].   
 
5.3 Calcitonin 
Calcitonin is a peptide hormone produced by the thyroid parafollicular cells, commonly 
named "C-cells," that regulate calcium homeostasis [80]. Increases in serum calcium 
activate the release of calcitonin from the C-cells, which consecutively inhibits bone 
resorption by the osteoclast and calcium absorption by the intestine. It was therefore one of 
the first agents to be used as a treatment for osteoporosis. As mentioned previously, several 
animal studies suggest that GLP-1RAs can affect bone metabolism indirectly via the release 
of calcitonin by thyroid C cells which express the GLP-1r [26, 81]. The expression of the 
GLP-1r in thyroid glands has indeed been documented in rodents [82], but there is an 
uncertainty regarding its expression in humans [83, 84]. Furthermore, basal and stimulated 
calcitonin did not change during 1 year of liraglutide treatment [85]. Our own work 
demonstrates that serum levels of calcitonin were indeed increased by exendin-4 treatment 
in ovariectomised mice [31], although this was not shown when mice were treated with 
liraglutide, suggesting once again that these two GLP-1 agonists may have a different 
mechanism of action.  
 
6 Conclusion 
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Based on several rodent studies, GLP-1 therapy emerges as one of the most promising anti-
diabetic therapy for treating the skeletal fragility associated with diabetes. It was shown to 
increase bone mass, improve trabecular and cortical architectures, enhance bone strength 
and tissue material properties, affecting the collagen compartment rather than the mineral 
one. The possible mechanisms of action of GLP-1RAs on the skeleton are illustrated in 
Figure 1. They are however still not very clear and different GLP-1RAs may have different 
means of action. Among the potential ones, the stimulation of bone blood flow by GLP-1RAs 
seems very interesting and extremely promising in situations of osteoporotic and diabetic 
fractures. Clinical data are however still lacking and those establishing the relationship 
between the GLP-1RA use and decrease fracture risk have been so far negative. There is 
therefore a need for long-term clinical studies comparing the skeletal effects of different 
GLP-1RAs.   
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Table 1: Summary of approved GLP-1RAs for the treatment of type 2 diabetes mellitus 
Active compound Drug name Marketed by Approved in Approved dose range 
Exenatide (or Exendin-4) Byetta Astra Zeneca AB 2006 5-10 µg twice daily 
Liraglutide Victoza Novo Nordisk A/S 2009 0.6-1.8 mg once daily 
Lixisenatide Lyxumia Sanofi Aventis Groupe 2013 10-20 µg once daily 
Exenatide (or Exendin-4) 
long acting release 
Bydureon Astra Zeneca AB 2011 2 mg once weekly 
Albiglutide 
Eperzan 
GlaxoSmithKline Trading Services 
Ltd 
2014 30-50 mg once weekly 
Dulaglutide Trulicity Eli Lilly Nederland B.V. 2014 0.75-1.5 mg once weekly 
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Figure 1: Simplified scheme of the possible skeletal effects of GLP-1RAs 
Page 23 of 23
joe@bioscientifica.com
Manuscript submitted for review to Journal of Endocrinology
